Co-Diagnostics (C970) Stock Overview

Operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. More details

C970 fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 99.9% below our estimate of its fair value

Revenue is forecast to grow 59.03% per year

Risk Analysis

Does not have a meaningful market cap (€4M)

Makes less than USD$1m in revenue ($508K)

Shareholders have been substantially diluted in the past year

Shares are highly illiquid

+ 1 more risk

C970 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW445,219 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

445,219 investors already sharing narratives

View all narratives

Co-Diagnostics, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Co-Diagnostics
Historical stock prices
Current Share Price	US$0.14
52 Week High	US$36.00
52 Week Low	US$5.16
Beta	1.4
1 Month Change	0%
3 Month Change	-97.21%
1 Year Change	-98.30%
3 Year Change	-99.62%
5 Year Change	-99.90%
Change since IPO	-99.56%

Recent updates

Shareholder Returns

	C970	DE Medical Equipment	DE Market
7D	0%	0.3%	-2.2%
1Y	-98.3%	-18.4%	3.4%

Return vs Industry: C970 underperformed the German Medical Equipment industry which returned -28.8% over the past year.

Return vs Market: C970 underperformed the German Market which returned -1.9% over the past year.

Price Volatility

Is C970's price volatile compared to industry and market?
C970 volatility
C970 Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	5.3%
Market Average Movement	5.0%
10% most volatile stocks in DE Market	12.3%
10% least volatile stocks in DE Market	2.5%

Stable Share Price: C970's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine C970's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	132	Dwight Egan	co-dx.com

Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus.

Co-Diagnostics, Inc. Fundamentals Summary

How do Co-Diagnostics's earnings and revenue compare to its market cap?
C970 fundamental statistics
Market cap	€3.63m
Earnings (TTM)	-€27.83m
Revenue (TTM)	€439.17k

8.3x

P/S Ratio

-0.1x

P/E Ratio

Is C970 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
C970 income statement (TTM)
Revenue	US$507.89k
Cost of Revenue	US$335.05k
Gross Profit	US$172.84k
Other Expenses	US$32.35m
Earnings	-US$32.18m

Last Reported Earnings

Sep 30, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-14.26
Gross Margin	34.03%
Net Profit Margin	-6,336.27%
Debt/Equity Ratio	0%

How did C970 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/04/01 02:25
End of Day Share Price	2026/01/02 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Co-Diagnostics, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jason McCarthy	Maxim Group
James Sidoti	Sidoti & Company, LLC

Co-Diagnostics (C970) Stock Overview

Rewards

Risk Analysis

Join community and earn perks

Co-Diagnostics, Inc. Competitors

NanoRepro

Geratherm Medical

aap Implantate

Redsense Medical

Price History & Performance

Recent News & Updates

Stadium Capital Llc Announces Proposes Settlement of Class Action Lawsuit Against Co-Diagnostics Inc

Co-Diagnostics Completes New Vector Smart Laboratory Installations In Florida And Indiana

Co-Diagnostics, Inc. Announces Executive Changes, Effective September 2, 2026

Co-Diagnostics Launches Integrated Cloud Infrastructure And Mobile Application For Point-Of-Care Mycobacterium Tuberculosis Test In India

Co-Diagnostics Submits FDA 510(k) Premarket Notification And CLIA Waiver By Application For Co-Dx PCR Flu A/B & RSV Upper Respiratory Multiplex Test On Co-Dx PCR Pro Instrument

Co-Diagnostics, Inc. to Report Q2, 2026 Results on Aug 13, 2026

Recent updates

Stadium Capital Llc Announces Proposes Settlement of Class Action Lawsuit Against Co-Diagnostics Inc

Co-Diagnostics Completes New Vector Smart Laboratory Installations In Florida And Indiana

Co-Diagnostics, Inc. Announces Executive Changes, Effective September 2, 2026

Co-Diagnostics Launches Integrated Cloud Infrastructure And Mobile Application For Point-Of-Care Mycobacterium Tuberculosis Test In India

Co-Diagnostics Submits FDA 510(k) Premarket Notification And CLIA Waiver By Application For Co-Dx PCR Flu A/B & RSV Upper Respiratory Multiplex Test On Co-Dx PCR Pro Instrument

Co-Diagnostics, Inc. to Report Q2, 2026 Results on Aug 13, 2026

Co-Diagnostics Appoints Wes Lindsey as Chief Scientific Officer

Co-Diagnostics, Inc., Annual General Meeting, Sep 03, 2026

Co-Diagnostics, Inc. Completes Clinical and Analytical Studies for Co-Dx Pcr Flu A/B & Rsv Upper Respiratory Multiplex Test in Preparation for Fda 510(K) Submission

Co-Diagnostics and Cosara Advance Ebola Pcr Test Development and Co-Dx Pcr Point-Of-Care Platform Capabilities

Co-Diagnostics Advances Ebola Pcr Assay Development Strategy with Joint Venture Cosara

Co-Diagnostics Inc Develops Ebola Assay Strategy

Co-Diagnostics, Inc. announced that it expects to receive $3 million in funding

Co-Diagnostics, Inc. to Report Q1, 2026 Results on May 14, 2026

Co-Diagnostics, Inc. Showcases Co-Dx Pcr Platform and Ce-Ivd Solutions At Escmid Global 2026 in Munich, Germany

Co-Diagnostics, Inc. to Report Q4, 2025 Results on Mar 31, 2026

Co-Diagnostics, Inc.(OTCPK:CODX) dropped from S&P TMI Index

Co-Diagnostics, Inc.(OTCPK:CODX) dropped from NASDAQ Composite Index

Co-Diagnostics Performs Analysis of Influenza Co-Primers®? to Confirm Reactivity Against Flu A H3n2 Mutation

Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx™? PCR Platform to Support Submission to the U.S. FDA

Co-Diagnostics, Inc. to Report Q3, 2025 Results on Nov 13, 2025

Co-Diagnostics, Inc. has completed a Follow-on Equity Offering in the amount of $6.999927 million.

Co-Diagnostics, Inc. has filed a Follow-on Equity Offering in the amount of $7 million.

Co-Diagnostics, Inc. has filed a Follow-on Equity Offering in the amount of $4.086645 million.

Co-Diagnostics, Inc. Announces Development of Proprietary Sample Prep Instrument for PoC Testing

Co-Diagnostics, Inc. has completed a Follow-on Equity Offering in the amount of $3.8476 million.

Co-Diagnostics, Inc. has filed a Follow-on Equity Offering in the amount of $3.8476 million.

Co-Diagnostics, Inc. Performs Analysis of Chikungunya Co-Primers to Confirm Reactivity Against Known Virus Strains

Co-Diagnostics, Inc. to Report Q2, 2025 Results on Aug 14, 2025

Co-Diagnostics, Inc. to Report Q1, 2025 Results on May 08, 2025

Co-Diagnostics, Inc., Annual General Meeting, May 28, 2025

Co-Diagnostics, Inc. to Report Q4, 2024 Results on Mar 27, 2025

Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit

Co-Diagnostics, Inc. Announces Intention to Submit Enhanced Version of COVID-19 Test to FDA for 510(k) Clearance

Co-Diagnostics Receives a Notice from Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.20 loss in 3Q 2023)

Co-Diagnostics, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Second quarter 2024 earnings released: US$0.25 loss per share (vs US$0.31 loss in 2Q 2023)

Co-Diagnostics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Co-Diagnostics, Inc., Annual General Meeting, Aug 29, 2024

Co-Diagnostics, Inc. Submits First FDA 510(k) Application for Co-Dx PCR Pro Platform

First quarter 2024 earnings released: US$0.31 loss per share (vs US$0.20 loss in 1Q 2023)

New minor risk - Shareholder dilution

Co-Diagnostics, Inc. to Report Q1, 2024 Results on May 09, 2024

Co-Diagnostics, Inc. Appoints Executive Appointments

Full year 2023 earnings released: US$1.20 loss per share (vs US$0.45 loss in FY 2022)

Co-Diagnostics, Inc. to Report Q4, 2023 Results on Mar 14, 2024

Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro

Third quarter 2023 earnings released: US$0.20 loss per share (vs US$0.043 loss in 3Q 2022)

Co-Diagnostics, Inc. to Report Q3, 2023 Results on Nov 09, 2023

Co-Diagnostics, Inc. Appoints Ivory Chang as Chief Regulatory Affairs Officer

Second quarter 2023 earnings released: US$0.31 loss per share (vs US$0.083 loss in 2Q 2022)

Co-Diagnostics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

New major risk - Share price stability

Co-Diagnostics, Inc., Annual General Meeting, Aug 30, 2023

Co-Diagnostics, Inc. Receives Funding for Co-Dx PCR Home Platform from NIH RADx Tech Program

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.34 profit in 1Q 2022)

Co-Diagnostics, Inc. to Report Q1, 2023 Results on May 11, 2023

Full year 2022 earnings released: US$0.45 loss per share (vs US$1.27 profit in FY 2021)

Third quarter 2022 earnings released: US$0.043 loss per share (vs US$0.40 profit in 3Q 2021)

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.043 loss per share (vs US$0.40 profit in 3Q 2021)